VALBIOTIS SA: Cardiovascular Prevention Act: A response to a major public health challenge A milestone fully aligned with Valbiotis’ mission

Cardiovascular Prevention Act:

A response to a major public health challenge

A milestone fully aligned with Valbiotis’ mission

La Rochelle, Monday, July 27, 2026 (5:40 PM CEST) – Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible), a French laboratory specializing in cardiometabolic health, welcomes the final and unanimous adoption by the French Parliament, on Monday, July 20, 2026, of the proposed legislation to accelerate cardiovascular and neurovascular prevention.

This legislation explicitly places the prevention of cardiovascular and neurovascular diseases at the heart of France’s national prevention strategy. It strengthens awareness-raising efforts on key risk factors, including high blood pressure, diabetes and high cholesterol, and expands screening for these conditions within existing programs, to support earlier detection and better lifelong monitoring. It also broadens the role of community-based healthcare professionals. Pharmacists are now authorized to measure blood pressure as part of preventive care. Lastly, the legislation also provides for workplace initiatives to raise awareness of cardiovascular and neurovascular risk factors.

Institutional recognition that aligns with Valbiotis’ mission

This legislation sends a strong message: prevention is becoming a cornerstone of the French healthcare system in the fight against cardiovascular and neurovascular diseases. This message directly echoes Valbiotis’ mission: to prevent cardiometabolic imbalances through early action, before disease develops. For more than 10 years, the Company has been developing and providing healthcare professionals and consumers with scientifically grounded, clinically tested solutions resulting from rigorous R&D to support effective, evidence-based prevention.

Three aspects of the text align directly with Valbiotis’ priorities: promoting prevention at key stages of life, strengthening awareness-raising initiatives and improving recognition of cardiometabolic risk in women, a Valbiotis commitment illustrated by the recent Cœur en Jeu (“Heart at Stake”) campaign and its support for the Agir pour le Cœur des Femmes Women’s Cardiovascular HealthcareFoundation.

This institutional recognition reinforces Valbiotis’ long-term approach, focused on scientific innovation and the prevention of cardiometabolic imbalances through clinically tested solutions designed to address patients' health needs with precision.

In practical terms, this commitment is already reflected in two initiatives: a dedicated training plan for healthcare professionals focused on preventing cardiometabolic imbalances, and the commercialization of the ValbiotisPRO® range. Developed through 10 years of R&D and clinically tested, the ValbiotisPRO® range currently includes three products (Cholesterol, Metabolic Health, Cardio-Circulation), complemented by five products in the ValbiotisPLUS® range targeting symptoms associated with cardiometabolic imbalances (Sleep, Serenity, Multivitamins, Omega-3, Magnesium).

Shareholder Benefit

20% discount on ValbiotisPRO® and ValbiotisPLUS® products, granted by customer service (service-client@valbiotis.com) upon presentation of proof of ownership of at least 85 shares

Terms and Conditions: Click here

About Valbiotis

Valbiotis is a French laboratory specializing in the development and distribution of scientifically tested dietary supplements designed to support health at every stage of life. Through an innovative approach combining scientific excellence, plant expertise and the richness of natural ingredients, Valbiotis offers a new generation of dietary supplements aimed at promoting cardio-metabolic balance and overall well-being, and addressing everyday health concerns such as sleep, fatigue, mood regulation, immunity and vitality. Created at the beginning of 2014 in La Rochelle, France, Valbiotis has forged numerous partnerships with leading academic centers.

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label.Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information on Valbiotis®, please visit: www.valbiotis.com

Contacts

Corporate Communication / Valbiotis

Caroline Lamberti

+ 33 6 77 82 56 88

caroline.lamberti@valbiotis.com

Financial Communication / Seitosei.Actifin

Marianne Py

+33 6 85 52 76 93

marianne.py@seitosei-actifin.com

Media Relations /LJ Com by JIN

Valentine Martin

+33 6 32 29 43 82 v.martin@ljcom.net

Name: Valbiotis ISIN Code: FR0013254851

Ticker Symbol: ALVAL

EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in Valbiotis' Universal Registration Document filed́ with the Autorité́ des marchés financiers (AMF) on April 26, 2023 under No. D.23-0347 as well as its Amendment filed with the AMF on December 11, 2023 under No. D. 23-0347.A01, available on the Company website (www.valbiotis.com).

This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.